FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017171454> ?p ?o ?g. }

• W2017171454 endingPage "1256" @default.
• W2017171454 startingPage "1217" @default.
• W2017171454 abstract "The aim of this article is to describe the current and potential clinical translation of pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases. The first section of the present review summarizes the available preclinical and clinical data with PARP inhibitors in various forms of cancer. In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-associated lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer. HRR defects are classically associated with BRCA1 and 2 mutations associated with familial breast and ovarian cancer, but there may be many other causes of HRR defects. Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects. Multiple lines of preclinical data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation. Both single agent and combination clinical trials are underway. The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clinical development. The second section of the present review summarizes the role of PARP in selected non-oncologic indications. In a number of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clinical translatability of PARP inhibition is supported by multiple lines of preclinical data, as well as observational data demonstrating PARP activation in human tissue samples. In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathology. Accordingly, multiple lines of preclinical data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses. As the clinical trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clinical investigations, aimed at testing of PARP inhibitors for various non-oncologic indications, will be initiated, as well." @default.
• W2017171454 created "2016-06-24" @default.
• W2017171454 creator A5032387920 @default.
• W2017171454 creator A5058049602 @default.
• W2017171454 date "2013-12-01" @default.
• W2017171454 modified "2023-09-30" @default.
• W2017171454 title "Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond" @default.
• W2017171454 cites W139007891 @default.
• W2017171454 cites W1489361481 @default.
• W2017171454 cites W1499143025 @default.
• W2017171454 cites W1523531555 @default.
• W2017171454 cites W1533729382 @default.
• W2017171454 cites W1543701118 @default.
• W2017171454 cites W1546873627 @default.
• W2017171454 cites W1566936870 @default.
• W2017171454 cites W1581913363 @default.
• W2017171454 cites W1584549675 @default.
• W2017171454 cites W1585852920 @default.
• W2017171454 cites W1598898771 @default.
• W2017171454 cites W1601281079 @default.
• W2017171454 cites W1601356608 @default.
• W2017171454 cites W1764470449 @default.
• W2017171454 cites W1774317821 @default.
• W2017171454 cites W1848063234 @default.
• W2017171454 cites W1877440701 @default.
• W2017171454 cites W188183793 @default.
• W2017171454 cites W1963711485 @default.
• W2017171454 cites W1963864317 @default.
• W2017171454 cites W1964338852 @default.
• W2017171454 cites W1964531991 @default.
• W2017171454 cites W1964968607 @default.
• W2017171454 cites W1966709769 @default.
• W2017171454 cites W1966928113 @default.
• W2017171454 cites W1967533893 @default.
• W2017171454 cites W1967893466 @default.
• W2017171454 cites W1969078294 @default.
• W2017171454 cites W1969302344 @default.
• W2017171454 cites W1969865402 @default.
• W2017171454 cites W1969916200 @default.
• W2017171454 cites W1970184435 @default.
• W2017171454 cites W1970366287 @default.
• W2017171454 cites W1970572497 @default.
• W2017171454 cites W1970910000 @default.
• W2017171454 cites W1971529544 @default.
• W2017171454 cites W1971545998 @default.
• W2017171454 cites W1972108672 @default.
• W2017171454 cites W1972429717 @default.
• W2017171454 cites W1972866949 @default.
• W2017171454 cites W1973123264 @default.
• W2017171454 cites W1973268287 @default.
• W2017171454 cites W1974045633 @default.
• W2017171454 cites W1974176915 @default.
• W2017171454 cites W1974300697 @default.
• W2017171454 cites W1975209874 @default.
• W2017171454 cites W1975255909 @default.
• W2017171454 cites W1975445106 @default.
• W2017171454 cites W1975490162 @default.
• W2017171454 cites W1975556106 @default.
• W2017171454 cites W1975837286 @default.
• W2017171454 cites W1975846526 @default.
• W2017171454 cites W1976927712 @default.
• W2017171454 cites W1977491006 @default.
• W2017171454 cites W1978367221 @default.
• W2017171454 cites W1978595257 @default.
• W2017171454 cites W1978989748 @default.
• W2017171454 cites W1979992960 @default.
• W2017171454 cites W1980223360 @default.
• W2017171454 cites W1980387577 @default.
• W2017171454 cites W1981280554 @default.
• W2017171454 cites W1981589068 @default.
• W2017171454 cites W1981754352 @default.
• W2017171454 cites W1981955278 @default.
• W2017171454 cites W1982785786 @default.
• W2017171454 cites W1982952782 @default.
• W2017171454 cites W1983598853 @default.
• W2017171454 cites W1984616391 @default.
• W2017171454 cites W1984629445 @default.
• W2017171454 cites W1984795781 @default.
• W2017171454 cites W1985740124 @default.
• W2017171454 cites W1986048010 @default.
• W2017171454 cites W1987414503 @default.
• W2017171454 cites W1988171492 @default.
• W2017171454 cites W1988194498 @default.
• W2017171454 cites W1989302474 @default.
• W2017171454 cites W1989445129 @default.
• W2017171454 cites W1990459210 @default.
• W2017171454 cites W1991124383 @default.
• W2017171454 cites W1992332625 @default.
• W2017171454 cites W1992413029 @default.
• W2017171454 cites W1992674106 @default.
• W2017171454 cites W1992806553 @default.
• W2017171454 cites W1993582972 @default.
• W2017171454 cites W1993899027 @default.
• W2017171454 cites W1994125700 @default.
• W2017171454 cites W1994127680 @default.
• W2017171454 cites W1994264346 @default.
• W2017171454 cites W1994432408 @default.
• W2017171454 cites W1995005155 @default.

• next